Opportunities
Search

Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Translational Research Award (TRA) supports translational research that will accelerate the movement of promising ideas in spinal cord injury (SCI) research into clinical applications.Distinctive Features:• This funding opportunity contains an Early-Career Partnership Option, which allows for two principal investigators (PIs). If this option is selected, at least one of the named PIs must be an early-career investigator. Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. If recommended for funding, each PI will be named on a separate award to the recipient organization(s). Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.• Applications to this funding opportunity must name at least one SCI community partner (e.g., SCI Lived-Experience Consultant, representative of community-based organizations) who will provide advice and consultation throughout the planning and implementation of the research project.

Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Clinical Translation Research Award (CTRA) supports high-impact, new, or emerging clinical research that requires additional preliminary studies, such as feasibility, pilot, or optimization, to prepare for future larger-scale clinical trials or implementation. Primary objectives of this mechanism include:• Accelerating the translation of current and emerging techniques or interventions into clinical use by addressing specific barrier(s) to clinical success for the purpose of de-risking or informing the design of definitive trials.• Identifying the most effective diagnosis, treatment and rehabilitation options to support critical decision-making for patients, clinicians, care partners and policymakers.Distinctive Features:• This funding opportunity contains an Early-Career Partnership Option, which allows for two principal investigators (PIs). If this option is selected, at least one of the named PIs must be an early-career investigator. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.• Applications to this funding opportunity must name at least two spinal cord injury (SCI) community partners who will provide advice and consultation throughout the planning and implementation of the research project.

Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of spinal cord injury (SCI).Distinctive Features: This funding opportunity contains an Early-Career Partnership Option, which allows for two Principal Investigators (PIs). If this option is selected, at least one of the named PIs must be an early-career investigator. Only the Initiating PI will submit a pre-application, but all PIs will need to submit full applications. The Partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. If recommended for funding, each PI will be named on a separate award to the recipient organization(s). Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.Applications to this funding opportunity must name at least two spinal cord injury (SCI) community partners (e.g., SCI Lived-Experience Consultants, representatives of community-based organizations) who will provide advice and consultation throughout the planning and implementation of the research project.

Expected Impact:FOR ALL THREE THEMATIC PRIORITIES:Expected impact at the closure of the project (non-exhaustive list): Innovative technologies tested and adopted by the market;Innovative solutions deployed improving businesses confidence, competences and means to digitalise and grow; Contribution to digitisation and health systems transformation, through various types of innovation and the supply of IT services;Uptake of technologically/economically reliable and viable solutions on the market;Deployment of new technologies fostering the growth of Europe’s manufacturing sector;Innovative technologies adopted by SMEs;Identification of possible sources of funding/funding mix, to cover the residual investment needs (public-private partnerships for the deployment of innovation, the collaboration with venture capitals, EIB group loans etc);Strengthening innovation diffusion channels;Reinforcin...

Expected Impact:FOR ALL THREE THEMATIC PRIORITIES:Expected impact at the closure of the project (non-exhaustive list):Creation of new value chains in less developed regions and transition regions;Application and deployment of innovative technologies and solutions (new tothe region) in less developed and transition regions (innovation diffusion);Exploitation of project results;Innovative technologies tested and adopted by the market;Innovative solutions deployed improving businesses confidence, competencesand means to digitalise and grow;Contribution to digitisation and health systems transformation, through varioustypes of innovation and the supply of IT services;Uptake of technologically/economically reliable and viable solutions on themarket;Deployment of new technologies fostering the growth of Europe’s manufacturing sector;Innovative technologies adopted by SMEs;Identification of pos...

Buyer: Miljødirektoratet | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-11-13

Buyer: Cargotor Sp. z o.o. | Notice type: cn-standard | Procedure: comp-dial | Contract: works | Deadline: 2026-11-13

Buyer: SADEV 94 | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-11-13

Buyer: СПЕЦИАЛИЗИРАНА БОЛНИЦА ЗА АКТИВНО ЛЕЧЕНИЕ НА ХЕМАТОЛОГИЧНИ ЗАБОЛЯВАНИЯ ЕАД | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2026-11-13

Buyer: СПЕЦИАЛИЗИРАНА БОЛНИЦА ЗА АКТИВНО ЛЕЧЕНИЕ НА ХЕМАТОЛОГИЧНИ ЗАБОЛЯВАНИЯ ЕАД | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2026-11-13

Buyer: Odense Kommune | Notice type: cn-standard | Procedure: oth-mult | Contract: services | Deadline: 2026-11-13

This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs that propose to support intensive supervised research training and career development experiences for clinician scientists (Scholars) leading to research independence in the area of substance use and substance use disorder research.

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated mid-phase clinical trials of natural products(i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. All applications submitted under this NOFO must be supported by sufficient preliminary data demonstrating bioavailability (if applicable) and documentation that the natural product produces a reproducible and measurable impact on target engagement (i.e., measure of the mechanism of action). Only in cases when it is not possible/practical to measure target engagement in the patient population of interest or when there is a fundamental understanding of the products mechanism of action will this preliminary data requirement be waived. Applications submitted to this NOFO should propose a mid-phase clinical trial to do the following: determine the optimal dose or formulation of a given natural product for use in a future multi-site efficacy trial; or determine which patient phenotypes will be responders versus non-responders to the natural product to inform inclusion/exclusion criteria of a future efficacy trial. Clinical trials submitted under this NOFO are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mi...

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This NOFO will provide up to 3 years support for studies to replicate the impact of the natural product on target engagement when used by humans, and assess whether there is an association between the degree of the impact on target engagement and functional or clinical outcomes in a patient population. Applications are encouraged to design studies to determine how to optimize the impact of the natural product on target engagement by optimizing the delivery of the natural product through examination of different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to engage the same target; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this NOFO are expected to be hy...

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, probiotics, and products marketed as dietary supplements), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This NOFO will provide up to three years (R61 phase) of support for milestone-driven testing of pharmacokinetics, bioavailability, and assessment of the natural products effect (i.e., measure of mechanism of action) when used by humans on a specified target measure. If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on target engagement(s) when used by humans and assess whether there is an association between the degree of the impact on the target engagement and clinical outcomes in a participant population. Applications are encouraged to design R33 studies to determine how to optimize the impact of the natural product on the target engagement by optimizing the delivery of the natural product through exami...

Buyer: SIEGVO | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-11-14

Buyer: Etat de Vaud, DGNSI - Direction générale du numérique et des systèmes d'information | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-11-16

Buyer: Landratsamt Rosenheim | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-11-16

Buyer: Landratsamt Rosenheim | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-11-16

Buyer: Ministerie van Defensie | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-16

Buyer: Gestió de Serveis Sanitaris | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-16

Buyer: Gestió de Serveis Sanitaris | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-16

Buyer: УНИВЕРСИТЕТСКА МНОГОПРОФИЛНА БОЛНИЦА ЗА АКТИВНО ЛЕЧЕНИЕ - Д-Р ГЕОРГИ СТРАНСКИ ЕАД | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2026-11-16

The Astronomy and Astrophysics Research Grants (AAG) Program is an inclusive and flexible funding opportunity to support research in the astronomical sciences. The Program provides individual investigator and collaborative research grants for observational, theoretical, laboratory, and archival data studies in astronomy and astrophysics. The Program also considers proposals for projects and tools that enable or enhance astronomical research. Proposals may span multiple disciplines and/or areas of study and may utilize multiple techniques.

The Advanced Technologies and Instrumentation for the Astronomical Sciences (ATI) program provides individual investigator and collaborative research grants for the development of new technologies and instrumentation for use in ground-based astronomy and astrophysics.The program supports achieving the science objectives of the Division of Astronomical Sciences. The development of innovative, potentially transformative, technologies and instruments are sought, even at high technical risk.Supported categories include (but are not limited to):advanced technology development, concept feasibility studies, and specialized instrumentation to enable new observations that are difficult or impossible to obtain with existing means.Proposals may include hardware and/or software development and/or analysis to enable new types of astronomical observations. Access to the ATI supported technology and instrumentation development efforts by the US astronomical community is viewed as an important metric of success. An annual Principal Investigators meeting is planned to disseminate information between the funded research efforts.